These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 20729265

  • 1. Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
    Liang W, Chen C, Shi J, Ren Z, Hu F, van Goor H, Singhal PC, Ding G.
    Nephrol Dial Transplant; 2011 Mar; 26(3):789-99. PubMed ID: 20729265
    [Abstract] [Full Text] [Related]

  • 2. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.
    Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M.
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1072-80. PubMed ID: 19940106
    [Abstract] [Full Text] [Related]

  • 3. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, Noma T, Kohno M, Nishiyama A, Nakano D.
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [Abstract] [Full Text] [Related]

  • 4. Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats.
    Liu W, Wang W, Song SW, Gu XF, Ma XJ, Su FY, Zhang H, Liu AJ, Su DF.
    J Cardiovasc Pharmacol; 2011 Mar; 57(3):308-16. PubMed ID: 21266915
    [Abstract] [Full Text] [Related]

  • 5. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
    Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T.
    Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434
    [Abstract] [Full Text] [Related]

  • 6. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.
    Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K, Iida M.
    Nephrol Dial Transplant; 2011 Aug; 26(8):2475-84. PubMed ID: 21220752
    [Abstract] [Full Text] [Related]

  • 7. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.
    Fogari R, Derosa G, Zoppi A, Preti P, Lazzari P, Destro M, Fogari E, Rinaldi A, Mugellini A.
    Am J Hypertens; 2007 Apr; 20(4):417-22. PubMed ID: 17386350
    [Abstract] [Full Text] [Related]

  • 8. Protective effects of eplerenone on podocyte injury in adriamycin nephropathy rats.
    Fang Z, Zhang C, He F, Chen S, Sun X, Zhu Z, Liu J, Meng X.
    J Huazhong Univ Sci Technolog Med Sci; 2011 Jun; 31(3):329. PubMed ID: 21671173
    [Abstract] [Full Text] [Related]

  • 9. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
    Nakano Y, Yoshimoto T, Fukuda T, Murakami M, Bouchi R, Minami I, Hashimoto K, Fujii Y, Kihara K, Ogawa Y.
    Intern Med; 2018 Sep 01; 57(17):2459-2466. PubMed ID: 29709927
    [Abstract] [Full Text] [Related]

  • 10. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
    Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T.
    Hypertension; 2006 Jun 01; 47(6):1084-93. PubMed ID: 16636193
    [Abstract] [Full Text] [Related]

  • 11. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.
    Whaley-Connell A, Habibi J, Wei Y, Gutweiler A, Jellison J, Wiedmeyer CE, Ferrario CM, Sowers JR.
    Am J Physiol Renal Physiol; 2009 May 01; 296(5):F1013-22. PubMed ID: 19261739
    [Abstract] [Full Text] [Related]

  • 12. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar 01; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 13. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK, Williams GH, Anderson R, Akhras KS, Bittman RM, Krause SL.
    Arch Intern Med; 2003 Jul 14; 163(13):1543-8. PubMed ID: 12860576
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1.
    Ren Z, Liang W, Chen C, Yang H, Singhal PC, Ding G.
    Cell Signal; 2012 Feb 14; 24(2):443-450. PubMed ID: 21982880
    [Abstract] [Full Text] [Related]

  • 15. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
    Fukuda A, Fujimoto S, Iwatsubo S, Kawachi H, Kitamura K.
    Nephrology (Carlton); 2010 Apr 14; 15(3):321-6. PubMed ID: 20470301
    [Abstract] [Full Text] [Related]

  • 16. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model.
    Zhou X, Ono H, Ono Y, Frohlich ED.
    Am J Nephrol; 2004 Apr 14; 24(2):242-9. PubMed ID: 15031627
    [Abstract] [Full Text] [Related]

  • 17. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.
    Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T.
    J Am Soc Nephrol; 2006 Dec 14; 17(12):3438-46. PubMed ID: 17082236
    [Abstract] [Full Text] [Related]

  • 18. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.
    Lamarre-Cliche M, de Champlain J, Lacourcière Y, Poirier L, Karas M, Larochelle P.
    Am J Hypertens; 2005 Jan 14; 18(1):56-64. PubMed ID: 15691618
    [Abstract] [Full Text] [Related]

  • 19. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA.
    Hypertension; 2003 May 14; 41(5):1021-6. PubMed ID: 12682082
    [Abstract] [Full Text] [Related]

  • 20. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.
    Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, Morikawa T, Okumura M, Meda I, Kiyomoto H, Hosomi N, Mori T, Ito S, Imanishi M.
    J Hypertens; 2008 Sep 14; 26(9):1849-59. PubMed ID: 18698221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.